Knowledge graph · Trial
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
TERMINATED
- Identifier
- CI-TRIAL-00010577
- Entity page
- /trial/NCT00103272 ↗
- Edges
- 32
- Neighbours
- 15 cancers2 drugs
- Drawn
- 17 of 17 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer condition of …CONDITION_OFderived15 of 30show all (up to 200) | ||||||||
| ← condition of | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 registry condition “Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)” mapped ALIAS | — | — | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | 1 | Observed | clinicaltrials | graph → |
| condition of | ||||||||